Investors sought for Auckland University's Sapvax cancer vaccine spin-out

Investors sought for Auckland University's Sapvax cancer vaccine spin-out
By Fiona Rotherham July 6 (BusinessDesk) -  Investors are being sought for US$8 million of funding to commercialise an anti-cancer vaccine using immunotherapy technology developed by a team led by Maurice Wilkins Centre director Rod Dunbar and Margaret Brimble, director of Auckland University’s medicinal chemistry programme. UniServices, the University of Auckland’s commercial arm, is setting up the spin-out company, Sapvax, to commercialise the patented vaccines. The research has run in parallel with that underway at the Malaghan Inst...